About Elite™ Hemagglutinin (H1N1) (A/California/07/09) ELISA Kit

Influenza A virus is a major cause of seasonal epidemics and global pandemics, with the 2009 pandemic H1N1 (A/California/07/2009) strain serving as the prototype virus of the H1N1pdm09 lineage. The viral hemagglutinin (HA) glycoprotein is the principal surface antigen responsible for binding sialic acid receptors on host cells, initiating viral entry, and eliciting protective neutralizing antibody responses. Because HA is the primary antigen used in influenza vaccines and a key target for therapeutic antibodies, accurate quantification of recombinant HA is essential for vaccine development, antigen production, virology research, and antiviral drug discovery.

The Elite™ Hemagglutinin (H1N1) (A/California/07/09) ELISA Kit is a highly sensitive streptavidin/biotin-based sandwich ELISA designed for the quantitative determination of Influenza A H1N1 (A/California/07/09) hemagglutinin (HA) in cell culture supernatants and serum samples. The assay provides a quantitative detection range of 0.03–30 ng/mL, offering excellent sensitivity and reproducibility for monitoring recombinant HA expression and vaccine antigen production. The kit is supplied in a 96-well microplate format and is compatible with standard ELISA readers operating at 450 nm, making it suitable for both routine laboratory research and high-throughput sample analysis.

Applications

Biological Significance of Influenza A H1N1 Hemagglutinin

Hemagglutinin is the major envelope glycoprotein of influenza A viruses and mediates the first step of viral infection by recognizing α2,6- or α2,3-linked sialic acid receptors on host cells, followed by receptor-mediated endocytosis and membrane fusion. As the dominant target of neutralizing antibodies, HA is also the primary antigen incorporated into seasonal influenza vaccines and remains the focus of universal influenza vaccine development. Continuous antigenic drift within the HA protein drives the emergence of new influenza variants and necessitates ongoing surveillance and vaccine reformulation. Quantitative analysis of H1N1 HA is therefore essential for recombinant protein production, vaccine potency evaluation, antigen characterization, immune response studies, and antiviral therapeutic development. The Elite™ Hemagglutinin (H1N1) (A/California/07/09) ELISA Kit provides a reliable, sensitive, and reproducible platform for influenza research, vaccine development, immunology, and biopharmaceutical manufacturing.